Longitudinal analysis of immune abnormalities in varying severities of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients.
Hardcastle, Sharni Lee, Brenu, Ekua Weba, Johnston, Samantha et al. · Journal of translational medicine · 2015 · DOI
Quick Summary
This study tracked immune system changes in 42 ME/CFS patients (divided into moderate and severe groups) and 18 healthy controls over 6 months. Researchers used blood tests to count different types of immune cells. They found that people with severe ME/CFS had noticeably different immune cell patterns than those with moderate ME/CFS or healthy controls, suggesting the immune system may work differently depending on how severe the illness is.
Why It Matters
This is the first study to systematically track immune abnormalities across different ME/CFS severity levels over time, suggesting that immune dysfunction may be severity-dependent. Identifying immune markers that change with disease severity could help develop better diagnostic tests and guide personalized treatment strategies for different patient populations.
Observed Findings
Severe CFS/ME patients had significantly increased naïve CD8+ T cells and γδ2 T cells at 6 months compared to controls and moderate patients.
Severe CFS/ME patients showed reduced CD56bright CD16dim NKG2D and CD56dim CD16- KIR2DL2/DL3 NK cell receptors at 6 months.
Moderate CFS/ME patients demonstrated increased iNKT CD62L expression over the 6-month period.
Severe CFS/ME patients had altered iNKT cell phenotypes, including increased CD56(-) CD16(-) and decreased CD94(-) CD11a(-) subsets.
Inferred Conclusions
Immune dysfunction in ME/CFS is severity-dependent, with distinct immune signatures differentiating severe from moderate disease.
Multiple immune compartments (NK cells, T cells, γδT cells) are involved in the immunological abnormalities of ME/CFS, particularly in severe patients.
Immune markers warrant further longitudinal investigation as potential biomarkers for disease severity stratification and monitoring.
Remaining Questions
Do these identified immune cell changes predict disease progression or prognosis in individual patients over longer follow-up periods?
What mechanisms drive the observed differences between moderate and severe CFS/ME immune profiles, and are they reversible with treatment?
What This Study Does Not Prove
This study does not prove that immune abnormalities cause ME/CFS—it only shows that certain immune cell patterns differ between patients and controls. The findings correlate immune changes with severity but do not establish whether these changes drive symptom severity or are consequences of the disease. Longitudinal changes over 6 months do not necessarily predict long-term patterns or inform prognosis.